Baudax Bio, Inc.
490 Lapp Road
Malvern, PA 19355
November 8, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Donald Field
Re: | Baudax Bio, Inc. | |
Registration Statement on Form 10 | ||
Filed October 22, 2019, as amended (FileNo. 001-39101) | ||
CIK No. 0001780097 |
Ladies and Gentlemen:
Reference is made to the Registration Statement on Form 10 (FileNo. 001-39101) (as amended to date, the “Registration Statement”), filed by Baudax Bio, Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “Commission”).
Recro Pharma, Inc. (“Recro”) has set November 15, 2019 as the record date for the distribution of the shares of common stock of the Company, which is scheduled to occur on November 21, 2019. Pursuant to Section 12(d) of the Securities Exchange Act of 1934, as amended, andRule 12d1-2 promulgated thereunder, the Company hereby requests that the effective date for the Registration Statement be accelerated to 4:00 p.m., Eastern time, on November 12, 2019, or as soon as practicable thereafter.
If the Commission has any questions or comments concerning this letter, or if you require any additional information, please feel free to contact Rachael M. Bushey of Pepper Hamilton LLP at (215)981-4331. The Company requests that it be notified of the effectiveness of the Registration Statement by a telephone call to Ms. Bushey.
| BAUDAX BIO, INC. | ||
By: | /s/ Gerri A. Henwood | |
Name: | Gerri A. Henwood | |
Title: | Chief Executive Officer | |
Baudax Bio, Inc. – Acceleration Letter
